Multiple cranial nerve palsies following COVID‐19 vaccination—Case report
Background The novel COVID‐19 vaccines have side effects that require efficient and close monitoring. Aims of the Study To examine whether the Pfizer‐BioNTech vaccine is associated with multiple cranial neuropathy. Methods We report the case of a 29‐year‐old male patient with no notable history who presented with left oculomotor, abducens, trigeminal and facial palsies 6 days after receiving the first dose of the Pfizer‐BioNTech COVID‐19 vaccine. Results Gadolinium‐enhanced MRI of the brain revealed enhancement in the left facial, trigeminal and oculomotor nerves, which persisted upon repeated examination. The cerebrospinal fluid analysis showed no sign of inflammation, both initially and after 1 month from the start of the patient's symptoms. Other causes were excluded by laboratory tests. The patient received high doses of corticosteroids, with improvement of symptoms. Conclusions In our case, the most probable etiology of the patient's multiple cranial neuropathy is the Pfizer‐BioNTech vaccine, which highlights the need for prolonged surveillance of COVID‐19 vaccine neurological complications..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:145 |
|---|---|
| Enthalten in: |
Acta neurologica Scandinavica - 145(2022), 2, Seite 257-259 |
| Beteiligte Personen: |
Manea, Maria Mirabela [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2022 John Wiley & Sons A/S |
|---|
| Umfang: |
3 |
|---|
| doi: |
10.1111/ane.13548 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY001749374 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY001749374 | ||
| 003 | DE-627 | ||
| 005 | 20230307110357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/ane.13548 |2 doi | |
| 028 | 5 | 2 | |a ANE_ANE13548.xml |
| 035 | |a (DE-627)WLY001749374 | ||
| 035 | |a (WILEY)ANE13548 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Manea, Maria Mirabela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multiple cranial nerve palsies following COVID‐19 vaccination—Case report |
| 264 | 1 | |c 2022 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2022 John Wiley & Sons A/S | ||
| 520 | |a Background The novel COVID‐19 vaccines have side effects that require efficient and close monitoring. Aims of the Study To examine whether the Pfizer‐BioNTech vaccine is associated with multiple cranial neuropathy. Methods We report the case of a 29‐year‐old male patient with no notable history who presented with left oculomotor, abducens, trigeminal and facial palsies 6 days after receiving the first dose of the Pfizer‐BioNTech COVID‐19 vaccine. Results Gadolinium‐enhanced MRI of the brain revealed enhancement in the left facial, trigeminal and oculomotor nerves, which persisted upon repeated examination. The cerebrospinal fluid analysis showed no sign of inflammation, both initially and after 1 month from the start of the patient's symptoms. Other causes were excluded by laboratory tests. The patient received high doses of corticosteroids, with improvement of symptoms. Conclusions In our case, the most probable etiology of the patient's multiple cranial neuropathy is the Pfizer‐BioNTech vaccine, which highlights the need for prolonged surveillance of COVID‐19 vaccine neurological complications. | ||
| 700 | 1 | |a Dragoș, Dorin |4 aut | |
| 700 | 1 | |a Enache, Iulia |4 aut | |
| 700 | 1 | |a Sirbu, Adrian George |4 aut | |
| 700 | 1 | |a Tuta, Sorin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta neurologica Scandinavica |d Oxford : Wiley-Blackwell, 1961 |g 145(2022), 2, Seite 257-259 |w (DE-627)WLY001744798 |w (DE-600)2001898-8 |x 16000404 |7 nnns |
| 773 | 1 | 8 | |g volume:145 |g year:2022 |g number:2 |g pages:257-259 |g extent:3 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.90 |q ASE |
| 951 | |a AR | ||
| 952 | |d 145 |j 2022 |e 2 |h 257-259 |g 3 | ||